1. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.
- Author
-
Kitchen, Scott G, Bennett, Michael, Galić, Zoran, Kim, Joanne, Xu, Qing, Young, Alan, Lieberman, Alexis, Joseph, Aviva, Goldstein, Harris, Ng, Hwee, Yang, Otto, and Zack, Jerome A
- Subjects
T-Lymphocytes ,Hematopoietic Stem Cells ,Animals ,Humans ,Mice ,Mice ,SCID ,HIV ,Receptors ,Antigen ,T-Cell ,Antigens ,Viral ,Epitopes ,Antiviral Agents ,Cloning ,Molecular ,Genetic Engineering ,Cell Differentiation ,Species Specificity ,Phenotype ,Antigens ,Viral ,Cloning ,Molecular ,SCID ,Receptors ,Antigen ,T-Cell ,General Science & Technology - Abstract
There is a desperate need for effective therapies to fight chronic viral infections. The immune response is normally fastidious at controlling the majority of viral infections and a therapeutic strategy aimed at reestablishing immune control represents a potentially powerful approach towards treating persistent viral infections. We examined the potential of genetically programming human hematopoietic stem cells to generate mature CD8+ cytotoxic T lymphocytes that express a molecularly cloned, "transgenic" human anti-HIV T cell receptor (TCR). Anti-HIV TCR transduction of human hematopoietic stem cells directed the maturation of a large population of polyfunctional, HIV-specific CD8+ cells capable of recognizing and killing viral antigen-presenting cells. Thus, through this proof-of-concept we propose that genetic engineering of human hematopoietic stem cells will allow the tailoring of effector T cell responses to fight HIV infection or other diseases that are characterized by the loss of immune control.
- Published
- 2009